MedPath

Oral NSAI Versus Acetaminophen or Placebo as a Discharge Treatment of Non Complicated Renal Colics

Phase 2
Recruiting
Conditions
Renal Colic
Interventions
Registration Number
NCT05722782
Lead Sponsor
University of Monastir
Brief Summary

Treatment with NSAI in renal colics has not been well investigated and there is no clear recommendations regarding this subject.

The aim of this study is to determine if an oral NSAI treatment is beneficial in patients discharged for the emergency department after the first line treatment of a renal colic investigating the reccurence of pain, the reconsultation rates and the admissions.

Detailed Description

Renal colic (RC) are a frequent cause of consultation in the emergency departement (ED). It counts for approximatively 20 % of patients presenting to the ED with severe acute onset abdominal pain.

The first line treatment of renal colics is based on NSAI drugs associated with antalgics and is further investigated in the NSAI vs Morphine study (NCT02156596) But there is no clear recommendations regarding the outpatient treatment of renal colics. Oral NSAI are still widely used as a second line medicine for this condition and variety of molecules were tried with non solid scientific arguments.

Piroxicam, a non-selective COX inhibitor drug appared to the oxicam class of NSAI, is widely used to treat rhumatoid and inflammatory disesases, and often prescribed in Tunisia as a second line treatment of RC.

In this study, the investigators aimed to investigate the efficiency and safety of the use of oral NSAI drugs (piroxicam) compared to Acetaminophen or placebo as a second line treatment of renal colics

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
500
Inclusion Criteria
  • Over 18 years old
  • Consenting to participate in the study
  • Patients treated in the ED for RC
  • No contraindications of NSAI or paracetamol treatment
Exclusion Criteria
  • Contraindication of NSAI treatment
  • Patients non reachable by telephone call
  • Patients that did not receive or use the treatment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboPlacebo: one pill per day for five days
NSAIPiroxicamPiroxicam: 20 mg per pill; one pill per day for five days
AcetaminophenAcetaminophenParacetamol: 1000 mg per day for five days
Primary Outcome Measures
NameTimeMethod
Efficacity of oral NSAI07 days

The efficacity of the oral NSAI treatment was evaluated at the seventh day by a telephone call, asking for the reccurence of pain, the reconsultation rates and intervals and the need for other treatments (antalgics...)

Secondary Outcome Measures
NameTimeMethod
Safety of NSAI07 days

Safety was evaluated by a telephone call asking for the occurence of NSAI side effects such as abdominal pain , vomiting , rush, bleeding or others

Trial Locations

Locations (1)

Fattouma Bourguiba University Hospital

🇹🇳

Monastir, Tunisia

© Copyright 2025. All Rights Reserved by MedPath